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Abstract Upon the discovery of RANK, RANKL and
OPG in the late 1990s, their importance in the maintenance
of the skeletal structure and their dramatic role in bone
disease were largely unexpected. In recent years the
understanding of these proteins, in particular their regula-
tion, has greatly increased. This review aims to bring the
interested reader up to date with the latest news and views
on the mechanisms controlling bone resorption in normal
and pathological conditions.
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Introduction
Bone is a specialised tissue with a complex composite
structure that enables it to perform multiple mechanical
and metabolic functions. In order to maintain these
functions within the body, bone is in a constant state of
remodelling. During this process, also known as bone
turnover, osteoclasts demineralise and resorb old bone and
osteoblasts deposit new bone to maintain a bone mass
appropriate to the stresses placed on the skeleton. Any
alteration in the process of bone turnover may alter bone
mineral density (BMD), bone strength and bone micro
architecture. This most commonly occurs when there is an
increase in osteoclast activity, leading to increased bone
resorption, resulting in diminished bone density (osteo-
penia). Osteopenia may also occur due to lack of
vitamin D (rickets and osteomalacia) or an excess of
parathyroid hormone (hyperparathyroidism). Disorders of
the skeleton may also involve an increase in BMD
(osteosclerosis), either due to defective osteoclast func-
tion (osteopetrosis), or as a result of too little parathyroid
hormone (hypoparathyroidism).
Molecular biological investigations have led to an
increased understanding of the mechanisms and proteins
involved in bone resorption. This process is controlled by a
system comprised of three key proteins, RANK (receptor-
activator of nuclear factor kappa beta), its ligand RANKL
(receptor-activator of nuclear factor kappa beta ligand) and
a decoy receptor OPG (osteoprotegerin). This system is
regulated by many osteotropic hormones and cytokines
which either reduce (glucocorticoids, inﬂammatory cyto-
kines e.g. interleukin-1 (IL-1), parathyroid hormone (PTH),
prostaglandin E2 (PGE2), vitamin D3) or increase (trans-
forming growth factor-b (TGF-b) and estrogens) the OPG/
RANKL ratio [1].
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RANK
RANK was discovered by Anderson et al. [2] by directly
sequencing cDNA from a human bone marrow-derived
myeloid dendritic cell. Sequencing of the RANK gene
showed it to be a type I transmembrane glycoprotein and
further gene mapping showed this newly discovered pro-
tein to be located on chromosome 18q22.1 [2] and also a
member of the tumour necrosis factor receptor (TNFR)
family [3]. The expression of RANK has since been found
on the surface of a wide variety of cells such as; osteoclast
precursors (circulating monocytes) [4], mature osteoclasts
[5], dendritic cells [2, 3], mammary gland epithelial cells
[6], breast cancer cells [7] and prostate cancer cells [8].
Human RANK (Fig. 1a)consistsof616aminoacids(aa).
These aa are divided into a C-terminal cytoplasmic domain
of 383 aa [2, 9], an N-terminal extracellular domain of 184
aa, a signal peptide of 28 aa and a transmembrane domain of
21 aa which contains four cysteine rich pseudo repeats and
two N-glycosylation sites [2, 9]. The signal peptide binds
with a signal recognition particle which determines the
destination site for the protein. Once bound, the signal pep-
tide is cleaved and the mature 588 aa protein is expressed on
the cell surface as a homotrimer [3, 10, 11].
RANKL
The cognate ligand for RANK, RANKL, was reported
almost simultaneously by four independent research groups
[2, 12–14]. RANKL is a tumour necrosis factor (TNF)-
related cytokine expressed by various bone cells including
osteoblasts and their immature precursors [15], T lympho-
cytes [16], B lymphocytes [17] and megakaryocytes [18].
RANKL (Fig. 1b) is coded for by a single gene, how-
ever, alternative splicing results in the expression of three
isoforms. In humans two of these isoforms are type II
transmembrane bound glycoproteins of either 317 [11]o r
270 aa, the latter differing only by a shorter intracellular
domain [19]. The third isoforms of only 243 aa lacks both
the transmembrane and cytoplasmic domains and acts as a
soluble ligand (sRANKL) [19, 20]. Each of these isoforms
is only capable of activating osteoclastogenesis when they
associate forming homotrimeric molecules [16, 21].
The human and murine RANKL proteins share 83–87%
homology, with the largest murine transmembrane isoform
being 316 aa [11]. Sequence analysis of the murine
RANKL gene (316 aa) compared to the human RANKL
gene (317 aa) showed two potential N-glycosylation sites
in the extracellular domain at amino acid fragment posi-
tions 197 and 263 [13].
Because of the existence of these splice variants in
RANKL it is likely that they are regulated differently and
have different functions. Although the exact explanations
for various isoforms are unknown, one possibility is that
membrane bound RANKL ensures cell–cell contact with
osteoclasts and their precursors whereas sRANKL allows
for diffusion to activate target cells. In the ﬁrst case, bone
resorption will be tightly localised to the cells expressing
RANKL ensuring topographically accurate remodelling. In
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be formed by shedding, a process in which RANKL is
cleaved from the cell surface membrane by sheddases such
as matrix metalloproteinase 14 (MMP-14) [22].
OPG
OPG was ﬁrst identiﬁed by sequence homology to the
TNFR family during a rat intestine cDNA sequencing
project [23]. They named the protein because of its pro-
tective effects in bone (Latin: os bone, protegere to
protect). OPG is a soluble glycoprotein secreted by various
mesenchymally derived cells such as osteoblasts [24] and
bone marrow stromal cells [25].
Unlike RANK and RANKL, OPG does not have a
transmembrane domain or cytoplasmic domain [2]. Com-
posed of 401 aa, human and murine OPG consist of four
cysteine rich pseudo repeats located in the N-terminal, two
death domains, a heparin binding site located in the
C-terminal and a 21 aa signal peptide [2] (Fig. 1c). The
four cysteine rich pseudo repeats form an elongated
structure and binds to one of the grooves of the active
RANKL trimer [20] therefore preventing RANKL/RANK
interaction and hence osteoclastogenesis.
This 401 aa structure gives OPG a monomeric molecular
weight of 60 kDa which is then assembled at the cys-400
residue in the heparin binding domain to form a 120 kDa
disulphide-linked dimer for secretion [26]. Prior to secre-
tion of both the monomeric and dimeric forms of OPG, the
signal peptide is cleaved from the N-terminal giving rise to
a 380 aa mature OPG protein [2, 23].
The function of RANK, RANKL and OPG
RANK
RANK activation by the binding of RANKL initiates an
internal signalling cascade via the cytoplasmic adaptor
proteins called TRAFs (Fig. 2). RANK has three binding
domains for TRAFs, each of which has a different binding
afﬁnity for either TRAF 2, 5 or 6 which relay the RANK
stimulation signal and activate downstream pathways
including NF-rB, c-jun N-terminal kinase (JNK) or Src
pathways. TRAF 6 in particular has been shown to be
necessary for the differentiation of osteoclastic cells [3]b y
enhancing Src kinase, essential for osteoclast function [27].
This signalling cascade results in the expression of various
genes and thus facilitates the differentiation of monocytes
into osteoclasts and also the activation of mature osteo-
clasts. One of these genes is nuclear factor of activated T
cells, calcineurin-dependent 1 (NFATc1) which results in
osteoclast differentiation and the expression of the osteo-
clast marker TRAP (tartrate resistant acid phosphatase)
[28].
RANKL
The expression of RANKL in human and murine osteo-
blastic cells is stimulated by various cytokines (IL-1, TNFa
and IL-11) [3, 29] and calciotrophic hormones including
PTH, 1,25dihydroxyvitamin D3 (1,25D3) and prostaglandin
E2 [29]. An increased production of RANKL by osteo-
blastic cells leads to osteoclast differentiation, activation
and survival, which results in increased bone resorption.
This, along with the involvement of the decoy receptor
OPG is thought to be a key mechanism in the control of
bone turnover.
The Wnt signalling pathway contains many proteins
involved in embryogenesis, cancer and normal physiolog-
ical processes and is a growing area of interest concerning
the regulation of bone turnover. In brief, when canonical
Wnt signalling is activated by one of the 19 secreted Wnts
binding to one of 10 frizzled receptors (Fzd), a signalling
cascade is initiated which results in the translocation of
b-catenin into the nucleus. Once here, b-catenin binds with
the transcription factor tcf/lef and initiates target gene
transcription. Wnt signalling has been shown to be vital for
normal osteoblast function [30–32]. sRANKL has been
reported to bind secreted frizzled related protein (sFRP)
[33], a soluble Wnt inhibitor produced by osteoblasts,
another mechanism by which osteoblasts can inhibit
osteoclast formation. This interaction may represent
another way in which bone resorption may be controlled at















Fig. 2 Schematic representation of RANK-RANKL binding signal-
ling pathways, indicating the inhibition of RANK-RANKL binding by
OPG
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OPG acts as a decoy receptor by binding with high afﬁnity
to RANKL therefore preventing the interaction with
RANK [34]. As a consequence of binding to RANKL,
OPG acts as an effective inhibitor of osteoclast differenti-
ation, activation and survival and therefore inhibits bone
resorption [34].
OPG expression and secretion by osteoblasts/stromal
cells are modulated by various metabolic regulators: IL-1,
TNF-a and TGF-b increase OPG secretion and it is
decreased by various stimulators of bone resorption
including PTH, PGE2 and 1,25D3 [15, 25, 29]. Using
mouse calvaria treated with indomethacin to block
endogenous prostaglandin production, the role of OPG in
modulating the adhesion of osteoclasts between the bone
surface and the endocranial membrane was investigated
[29]. These authors found that OPG inhibited both the
release of osteoclasts from the periosteum and adherence of
the osteoclasts to the bone surface, therefore inhibiting
bone resorption [29].
OPG has been shown to bind to TNF-related apoptosis
inducing ligand (TRAIL) [35] although with less afﬁnity
than for RANKL [36]. TRAIL is a 33–34 kDa cell asso-
ciated ligand which mediates apoptotic cell death
particularly in cancer cells. TRAIL binds to speciﬁc cell
surface receptors which contain cytoplasmic death
domains. Following this binding, TRAIL transduces an
apoptotic signal [37]. The binding of OPG to TRAIL was
found to inhibit TRAIL-induced apoptosis of Jurkat cells in
culture [35]. However, the biological signiﬁcance of the
binding of OPG to TRAIL remains unclear. OPG also has a
basic heparin binding domain making interactions with
heparin and heparin sulphates possible. Heparin sulphates
are expressed on the cell surface as heparin sulphate pro-
teoglycans (HSPGs). HSPGs are involved in cell-surface
signalling, controlling cell behaviour, actin cytoskeleton
regulation, cell adhesion and migration [4].
RANK, RANKL and OPG in disease
There are several inherited human conditions primarily
caused by a defect in the osteoclast resulting from a genetic
mutation in RANK, RANKL or OPG (summarised in
Table 1). There are two ways in which osteoclast activity
can be defective. They can be under-active resulting in an
excess of bone (osteopetrosis) or they can be over-active
resulting in too little bone (osteoporosis and familial ex-
pansile osteolysis [FEO]) [38].
RANK
FEO is an inherited autosomal dominant disease with
100% penetrance resulting from the constitutive activation
of RANK due to an 18-base pair tandem duplication. FEO
is characterized by deafness which often occurs before the
age of 10, early loss of teeth due to the resorption of the
cervical region (where a tooth meets the gum), osteolytic
lesions from late teenage years until late middle age [39]
and increased bone remodelling [38]. Lesions in FEO
mostly affect the tibia, ulna, humerus and femur, sparing
the axial skeleton such as the skull and pelvis which
are common sites for lesions found in Paget’s disease of
bone [39].
Another autosomal dominant disease caused by a
mutation in RANK is early-onset Paget’s disease [39, 40]
which differs from classical Paget’s disease by its early
onset and instead of lesions being restricted to one or more
bones they are scattered throughout the body. The patients
studied with early-onset Paget’s disease all presented
with bone pain and/or deformity in their teens and early
twenties and showed a 27-base pair duplication in the




in RANK-mediated activation of NF-rB, stimulation of
Table 1 A summary of human diseases caused by mutations in the RANK, RANKL and OPG genes
Gene Mutation Disease Reference
RANK 18 bp duplication Familial expansile osteolysis [39]
27 bp duplication Early onset Paget’s disease [39]
15 bp duplication Expansile skeletal hyperphosphatasia [42]
RANKL Deletion of amino acids 145-177 Autosomal recessive osteopetrosis [43]
A single nucleotide change (596T-A) in exon 8 of both alleles Autosomal recessive osteopetrosis [43]
Deletion of two nucleotides (828_829delCG) Autosomal recessive osteopetrosis [43]
OPG Deletion making OPG inactive Juvenile Paget’s disease [44]
20 bp deletion resulting in premature termination of OPG translation Juvenile Paget’s disease [47]
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[39].This stimulationinboneturnover leads topatients with
early-onset Paget’s disease to have enlarged and softened
bones, particularly those that are long and weight bearing
[38].
Expansile skeletal hyperphosphatasia (ESH) is an auto-
somal dominant disorder characterized by the premature
loss of teeth, early-onset deafness, episodic hypocalcaemia,
accelerated bone remodelling and widening of long bones
causing pain in the ﬁnger bones [41]. Mutation screening of
patients suffering from ESH revealed a 15-base pair tan-
dem duplication in the signal peptide region of the RANK
gene [42]. This mutation has the same affect on RANK as
seen in FEO; however, there is not a great increase in
osteoclast and osteoblast number and activity [38]. Anti-
resorptive therapy with bisphosphonates can be effective in
the treatment of FEO, early-onset Paget’s disease and ESH
[40], although very recently it has been reported that bis-
phosphonate toxicity during childhood can impair one
remodelling and induce osteopetrosis during later life [41].
RANKL
Autosomal recessive osteopetrosis is a rare genetic bone
disease. Bone biopsies taken from four unrelated individ-
uals with this disease showed an absence of osteoclasts and
no improvement in bone remodelling following haemato-
poietic stem cell transplantation, which would be expected
to replace the osteoclast population but not the osteoblast
[43]. Genetic analysis of the RANKL gene in these four
individuals revealed three different mutations. Patient one
had an in-frame deletion of amino acids 145–177. The
mutation deleted the entire bA strand and half of the AA
loop, which are essential for the osteoclastogenic activity
of RANKL. The second and third patients had a single
nucleotide change (596T-A) in exon 8 of both alleles. The
fourth patient had a genomic deletion of two nucleotides
(828_829delCG), resulting in a frame shift starting at
val277 and a premature stop codon. This mutation was
thought to cause the loss of the bF, bG and bH strands of
RANKL. These are all important for RANKL trimerisation
and therefore the mutation would prevent the activation of
osteoclastogenesis [43].
OPG
Mutations in the OPG gene cause a disease called juvenile
Paget’s disease, also known as idiopathic hyperphospha-
tasia [44]. This disease can be fatal if not treated with anti
bone resorption drugs [45]. Juvenile Paget’s disease is an
autosomal recessive osteopathy which initially presents in
infancy or early childhood and is characterized by rapidly
remodelling woven bone, osteopenia, fractures, progressive
skeletal deformity and increased bone remodelling
throughout the skeleton [44, 45]. Individuals with this
disease are also typically short in stature [46]. The location
and type of gene mutation responsible for this disease was
investigated by various groups.
The ﬁrst group studied nine children from two gener-
ations of a family from New Zealand, three of whom
displayed typical clinical and radiographical symptoms of
juvenile Paget’s disease. Biochemical analysis of the bone
turnover markers ALP and N-telopeptide/creatinine ratio
showed signiﬁcantly raised levels in the three affected
individuals. PCR analysis of each of the ﬁve exons of
OPG identiﬁed a 3-base pair in-frame deletion of a crit-
ical aspartate residue in exon three. OPG was also
detected in the plasma of the three affected children
suggesting that the mutation does not affect secretion. The
activity of the mutant OPG protein was then compared to
the normal functional protein. This revealed that normal
OPG inhibited bone resorption in mouse calvaria whereas
the mutant protein did not. This suggests the mutant OPG
with the three base pair deletion is inactive and results in
uncontrolled bone remodelling and increased bone turn-
over [44].
The second group investigated two unrelated Navajo
patients with juvenile Paget’s disease. Patient one was a
one-year-old male child with bone deformities as a result
of the disease. Patient two was a 26-year-old Navajo
female who was deaf, severely deformed and incapaci-
tated by the disease. The bone turnover marker, serum
alkaline phosphatase (ALP) activity was approximately 10
times above the normal range in both the male and female
patient [45] indicating excessive osteoblastic activity.
They then analyzed and sequenced the gene for OPG.
PCR analysis of genomic DNA from patient one and his
parents revealed no OPG gene product. Southern blotting
of genomic DNA supported this ﬁnding conﬁrming a
100 kilo base deletion that had completely deleted the
gene for OPG [45].
A third mutation of OPG in juvenile Paget’s disease was
identiﬁed [47]. This group studied 10 affected individuals,
each of these subjects had long-bone deformities, short
stature, raised ALP activity, impaired mobility (7/10 sub-
jects) and enlargement of the skull (6/10 subjects). PCR
analysis revealed that three of the 10 individuals had a 3-
base pair mutation of OPG. Other affected individuals had
a much larger 20-base pair deletion also in exon three of
the OPG protein. It is suggested that this mutation results in
premature termination of OPG protein translation [47]. As
with the 3-base pair deletion [44] and the 100 kb deletion
[45] the 20-base pair deletion resulted in increased bone
turnover, demonstrating that mutations in the OPG gene
can cause autosomal recessive idiopathic hyperphosphata-
sia [47, 48].
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The RANK, RANKL and OPG system is also involved
with many other metabolic bone diseases, where their
expression is modulated either directly or indirectly by the
tumour cell to promote its own survival. Bone metastases
are unfortunately a common occurrence in patients with
solid tumours such as breast cancer, prostate cancer and
lung cancer often resulting in severe pain and pathological
fractures amongst other complications [49]. Patients with
solid tumours metastatic to bone have been shown to have
a severe disruption in the RANK/RANKL/OPG system
[50]. In these instances, quality of life and even life
expectancy is dramatically reduced.
Breast cancer commonly metastasises to the skeleton
causing painful osteolytic lesions [51]. Establishment of
the metastatic tumour is gained by inﬂuencing the
expression ratio of RANKL and OPG to favour bone
resorption [51]. It is believed that some genes may pre-
dispose the likelihood for breast cancer to metastasise to
bone [52].
Bone is the most common and sometimes the only site
of metastasis in patients with advanced prostate cancer
[53]. Prostatic bone metastases stimulate an increase in
both rate of bone remodelling and bone volume [54].
Prostate cancer bone metastases produce RANKL thus
enabling them to induce osteolysis through osteoclast
activation [55]. Although mostly osteoblastic in nature,
prostatic bone metastases can also appear osteolytic in
order to promote tumour growth [54].
Lung cancer metastasises to bone in approximately 9–
30% of all cases [56]. Lung cancer metastases are generally
lytic in nature, although some have been found to also have
osteoblastic characteristics [57]. Constitutive expression of
the chemokine CCL22 by osteoclasts is thought in some
cases to potentially promote the metastasis of lung cancer
to bone [58].
Multiple myeloma (MM) is an osteolytic bone disease
resulting from excessive bone resorption [59]. Although
the exact mechanisms of invasion are unclear, it is believed
the tumour invades surrounding bone by up regulating
RANKL and down regulating OPG and therefore stimu-
lating local bone resorption [59].
Murine knockout models
RANK
RANK deﬁcient mice (RANK -/-) were generated in
order to investigate the direct role of RANK in bone
resorption [60]. RANK -/- mice were recognisable by
their small-body size, shortened limbs and doming of the
skull, which became apparent after weaning at 3 weeks of
age. At 6 weeks radiography revealed an osteopetrotic
phenotype including shortened long bones and increased
radio-density in bone marrow cavities relative to the con-
trol mice (RANK ?/?). Histological analysis showed
disorganized chondrocytes at the growth plates and poorly
remodelled osteocartilagenous structures blocking the
marrow cavities. Staining for the osteoclast marker TRAP
showed positively stained mature osteoclasts in the control
mice, yet they were completely absent in the RANK -/-
mice, suggesting an explanation for the osteopetrotic phe-
notype observed. The lack of RANK for RANKL to bind to
inhibited osteoclast differentiation and maturation, causing
a deﬁciency of mature osteoclasts at the bone surface [60].
RANKL
The requirement of RANKL for osteoclastogenesis and
bone remodelling, along with its function in modulating
immune responses was investigated using RANKL -/-
mice [5]. Similar to RANK -/- mice, RANKL -/- mice
showed a normal rate of growth until weaning at 3 weeks
old. After weaning their growth became severely stunted
and teeth failed to erupt [34]. The RANKL -/- mice
completely lacked TRAP positive stained osteoclasts, in
contrast to the large number of TRAP positive cells in the
RANKL ?/? control mice [5]. Radiographs showed
osteopetrosis was visible from 2 days after birth, with
shortened long bones with distinct broadening of the
epiphyses. The axial skeleton (skull, vertebrae, sternum,
breastbone and ribs) when visualized by X-ray showed a
large increase in radio-density, 516 mg cm
-3 in RANKL
-/- mice compared with 242 mg cm
-3 in RANKL ?/
? mice [5].
OPG
OPG and its physiological role as a regulator of normal
bone mass was investigated using targeted deletion of the
gene in mice (OPG -/-)[ 50]. They found an increased
mortality between birth and 4 weeks of age in OPG -/-
mice when compared to the OPG ?/? control mice. The
OPG -/- mice also had a higher prevalence of vertebral
and bone fractures in the ﬁrst 2 weeks of life indicating
brittle bones and a possibility of low-bone density. OPG
-/- mice that survived past weaning were fertile and
females successfully carried litters to term. Offspring were
also OPG -/- indicating that OPG is not required for
normal embryonic development [61].
Radiography showed decreased BMD in OPG -/- mice
compared to the OPG ?/? control mice, however, this was
only evident from 1 month of age and became more
prominent as the mice aged [61]. Histological examination
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severe osteoporosis with almost a complete lack of tra-
beculae by 1–2 months of age [61]. OPG -/- mice have
been shown to have a high bone turnover rate, disorganized
matrix and an impaired attachment of new to old bone in
the cement line due to excessive osteoclast activity [62].
Therefore, OPG plays a crucial role in blocking bone
resorption. Radiographic investigation of a transgenic
increase of OPG in mice revealed clear signs of osteope-
trosis immediately following birth, with the severity
increasing throughout adolescence and adult life [23].
Conclusion
With the discovery of RANKL came the ability to manu-
facture osteoclasts in vitro, which has accelerated up the
discovery of other factors that affect bone loss and
molecular details of differentiation and bone resorption.
Further to this came the understanding of RANKL and
OPG in diseases where bone is lost. This knowledge has
provided new targets for modern therapies, for example re-
engineered OPG and anti-RANKL antibodies.
Denusomab (AMG162) is a high afﬁnity anti-RANKL
antibody [63] able to prevent RANK/RANKL binding and
inhibit bone resorption resulting in an increased bone mass.
Denusomab is currently in phase III clinical trials for
treatment of osteoporosis [63, 64] and also under investi-
gation for the treatment of osteolytic bone metastases from
diseases such as breast cancer (phase II clinical trials) [65],
rheumatoid arthritis (phase II clinical trials) [66] and
multiple myeloma [67]. Similar attempts have also been
made with OPG [68, 69]. AMGN-0007 is a recombinant
OPG construct and suppressed bone resorption when
administered to MM and breast cancer patients during a
phase I clinical trial [68]. A similar result has been
observed using a recombinant adeno-associated viral
(rAAV) vector in mouse model of osteolytic breast cancer
[69].
Treatment of metastases to bone and their mechanisms
of action remain elusive. Use of bisphosphonates, a com-
mon drug for the treatment of osteoporosis, has proved to
be useful in preventing some metastases from breast,
prostate and lung cancer by inhibiting the osteoclast [70].
Bisphosphonate treatment also has the added beneﬁt of
reducing bone pain caused by the metastases that general
analgesics can sometimes fail to relieve [70]. Recent in
vitro studies for the prevention/reduction in skeletal
metastases include the intravenous administration of
RANK-Fc, a chimeric protein that inhibits the RANK/
RANKL interaction [57]. Treatment with RANK-Fc
reduced osteoclastogenesis, reduced bone tumour volume
and inhibited the lytic nature of the lesion [57].
Current publications also tend to discuss the function of
these proteins in bone remodelling or they discuss the
diseases that revolve around them. Here we have provided
an in-depth synopsis of the structures of the RANK,
RANKL and OPG proteins including structural diagrams
and combined this with an in-depth review of diseases
linked to these proteins. We have also reviewed how the
osteoblast integrates systemic signals from calciotropic
hormones like PTH and 1,25D3, and local signals from
growth factors and cytokines to stimulate or inhibit bone
resorption.
The discovery of the osteoclast differentiation factor
RANKL, its receptor RANK and its decoy receptor OPG,
has revolutionised our understanding of bone remodelling.
There is currently a large wealth of knowledge already in
publication surrounding RANK, RANKL and OPG
although many questions remain unanswered.
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